Table of Contents Author Guidelines Submit a Manuscript
Oxidative Medicine and Cellular Longevity
Volume 2017, Article ID 4809751, 8 pages
https://doi.org/10.1155/2017/4809751
Review Article

A Review of mTOR Pathway Inhibitors in Gynecologic Cancer

Brazilian National Cancer Institute (INCA), Rio de Janeiro, RJ, Brazil

Correspondence should be addressed to Andréia Cristina de Melo; rb.moc.lou@aierdna.olem

Received 3 November 2016; Accepted 12 January 2017; Published 13 February 2017

Academic Editor: Yasuhiro Maejima

Copyright © 2017 Andréia Cristina de Melo et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. S. Movva, L. Rodriguez, H. Arias-Pulido, and C. Verschraegen, “Novel chemotherapy approaches for cervical cancer,” Cancer, vol. 115, no. 14, pp. 3166–3180, 2009. View at Publisher · View at Google Scholar · View at Scopus
  2. N. Husseinzadeh and H. D. Husseinzadeh, “mTOR inhibitors and their clinical application in cervical, endometrial and ovarian cancers: A critical review,” Gynecologic Oncology, vol. 133, no. 2, pp. 375–381, 2014. View at Publisher · View at Google Scholar · View at Scopus
  3. D. Morgensztern and H. L. McLeod, “PI3K/Akt/mTOR pathway as a target for cancer therapy,” Anti-Cancer Drugs, vol. 16, no. 8, pp. 797–803, 2005. View at Publisher · View at Google Scholar · View at Scopus
  4. S. Chan, “Targeting the mammalian target of rapamycin (mTOR): a new approach to treating cancer,” British Journal of Cancer, vol. 91, no. 8, pp. 1420–1424, 2004. View at Publisher · View at Google Scholar · View at Scopus
  5. N. Sadeghi and D. E. Gerber, “Targeting the PI3K pathway for cancer therapy,” Future Medicinal Chemistry, vol. 4, no. 9, pp. 1153–1169, 2012. View at Publisher · View at Google Scholar · View at Scopus
  6. S. H. Advani, “Targeting mTOR pathway: a new concept in cancer therapy,” Indian Journal of Medical and Paediatric Oncology, vol. 31, no. 4, pp. 132–136, 2010. View at Publisher · View at Google Scholar · View at Scopus
  7. K. D. Courtney, R. B. Corcoran, and J. A. Engelman, “The PI3K pathway as drug target in human cancer,” Journal of Clinical Oncology, vol. 28, no. 6, pp. 1075–1083, 2010. View at Publisher · View at Google Scholar · View at Scopus
  8. J. LoPiccolo, G. M. Blumenthal, W. B. Bernstein, and P. A. Dennis, “Targeting the PI3K/Akt/mTOR pathway: effective combinations and clinical considerations,” Drug Resistance Updates, vol. 11, no. 1-2, pp. 32–50, 2008. View at Publisher · View at Google Scholar · View at Scopus
  9. I. Diaz-Padilla, I. Duran, B. A. Clarke, and A. M. Oza, “Biologic rationale and clinical activity of mTOR inhibitors in gynecological cancer,” Cancer Treatment Reviews, vol. 38, no. 6, pp. 767–775, 2012. View at Publisher · View at Google Scholar · View at Scopus
  10. http://seer.cancer.gov/statfacts/html/corp.html.
  11. http://fundedresearch.cancer.gov/nciportfolio/search/funded?type=site&fy=PUB2013.
  12. http://www.clinicaltrials.gov.
  13. N. Colombo, C. Creutzberg, F. Amant et al., “ESMO-ESGO-ESTRO consensus conference on endometrial cancer: diagnosis, treatment and follow-up,” Annals of Oncology, vol. 27, no. 1, pp. 16–41, 2016. View at Google Scholar
  14. NCCN Guidelines v2.2016 for Uterine Cancer, https://www.nccn.org/professionals/physician_gls/pdf/uterine.pdf.
  15. J. V. Bokhman, “Two pathogenetic types of endometrial carcinoma,” Gynecologic Oncology, vol. 15, no. 1, pp. 10–17, 1983. View at Publisher · View at Google Scholar · View at Scopus
  16. C. Kandoth, N. Schultz, A. D. Cherniack et al., “Integrated genomic characterization of endometrial carcinoma,” Nature, vol. 497, pp. 67–73, 2013. View at Google Scholar
  17. A. M. Oza, L. Elit, M.-S. Tsao et al., “Phase II study of temsirolimus in women with recurrent or metastatic endometrial cancer: a trial of the NCIC Clinical Trials Group,” Journal of Clinical Oncology, vol. 29, no. 24, pp. 3278–3285, 2011. View at Publisher · View at Google Scholar · View at Scopus
  18. A. M. Oza, S. Pignata, A. Poveda et al., “Randomized phase II trial of ridaforolimus in advanced endometrial carcinoma,” Journal of Clinical Oncology, vol. 33, no. 31, pp. 3576–3582, 2015. View at Publisher · View at Google Scholar · View at Scopus
  19. S. M. Temkin, S. D. Yamada, and G. F. Fleming, “A phase I study of weekly temsirolimus and topotecan in the treatment of advanced and/or recurrent gynecologic malignancies,” Gynecologic Oncology, vol. 117, no. 3, pp. 473–476, 2010. View at Publisher · View at Google Scholar · View at Scopus
  20. B. M. Slomovitz, K. H. Lu, T. Johnston et al., “A phase 2 study of the oral mammalian target of rapamycin inhibitor, everolimus, in patients with recurrent endometrial carcinoma,” Cancer, vol. 116, no. 23, pp. 5415–5419, 2010. View at Publisher · View at Google Scholar · View at Scopus
  21. I. Ray-Coquard, L. Favier, B. Weber et al., “Everolimus as second- or third-line treatment of advanced endometrial cancer: ENDORAD, a phase II trial of GINECO,” British Journal of Cancer, vol. 108, no. 9, pp. 1771–1777, 2013. View at Publisher · View at Google Scholar · View at Scopus
  22. N. Colombo, D. S. McMeekin, P. E. Schwartz et al., “Ridaforolimus as a single agent in advanced endometrial cancer: results of a single-arm, phase 2 trial,” British Journal of Cancer, vol. 108, no. 5, pp. 1021–1026, 2013. View at Publisher · View at Google Scholar · View at Scopus
  23. K. Behbakht, M. W. Sill, K. M. Darcy et al., “Phase II trial of the mTOR inhibitor, temsirolimus and evaluation of circulating tumor cells and tumor biomarkers in persistent and recurrent epithelial ovarian and primary peritoneal malignancies: a Gynecologic Oncology Group study,” Gynecologic Oncology, vol. 123, no. 1, pp. 19–26, 2011. View at Publisher · View at Google Scholar · View at Scopus
  24. U. Matulonis, I. Vergote, F. Backes et al., “Phase II study of the PI3K inhibitor pilaralisib (SAR245408; XL147) in patients with advanced or recurrent endometrial carcinoma,” Gynecologic Oncology, vol. 136, no. 2, pp. 246–253, 2015. View at Publisher · View at Google Scholar · View at Scopus
  25. A. P. Myers, R. R. Broaddus, V. Makker, P. A. Konstantinopoulos, R. Drapkin, and N. S. Horowitz, “Phase II, two-stage, two-arm, PIK3CA mutation stratified trial of MK-2206 in recurrent endometrial cancer (EC),” Journal of Clinical Oncology, vol. 31, supplement, abstract 5524, 2013, Proceedings of the 2013 ASCO Annual Meeting. View at Google Scholar
  26. G. F. Fleming, V. L. Filiaci, B. Marzullo et al., “Temsirolimus with or without megestrol acetate and tamoxifen for endometrial cancer: a gynecologic oncology group study,” Gynecologic Oncology, vol. 132, no. 3, pp. 585–592, 2014. View at Publisher · View at Google Scholar · View at Scopus
  27. B. M. Slomovitz, Y. Jiang, M. S. Yates et al., “Phase II study of everolimus and letrozole in patients with recurrent endometrial carcinoma,” Journal of Clinical Oncology, vol. 33, no. 8, pp. 930–936, 2015. View at Publisher · View at Google Scholar · View at Scopus
  28. P. T. Soliman, S. N. Westin, D. A. Iglesias et al., “Phase II study of everolimus, letrozole, and metformin in women with advanced/recurrent endometrial cancer,” Journal of Clinical Oncology, vol. 34, supplement, abstract 5506, 2016, Proceedings of the 2016 ASCO Annual Meeting. View at Google Scholar
  29. E. A. Alvarez, W. E. Brady, J. L. Walker et al., “Phase II trial of combination bevacizumab and temsirolimus in the treatment of recurrent or persistent endometrial carcinoma: a Gynecologic Oncology Group study,” Gynecologic Oncology, vol. 129, no. 1, pp. 22–27, 2013. View at Publisher · View at Google Scholar · View at Scopus
  30. M. H. Einstein, R. M. Wenham, and R. Morgan, “Phase II trial of temsirolimus and bevacizumab for initial recurrence of endometrial cancer,” Journal of Clinical Oncology, vol. 30, supplement, abstract 5025, 2012, Proceedings of the 2012 ASCO Annual Meeting. View at Google Scholar
  31. C. Aghajanian, V. L. Filiaci, D. S. Dizon et al., “A randomized phase II study of paclitaxel/carboplatin/bevacizumab, paclitaxel/carboplatin/temsirolimus and ixabepilone/carboplatin/bevacizumab as initial therapy for measurable stage III or IVA, stage IVB or recurrent endometrial cancer, GOG-86P,” Journal of Clinical Oncology, vol. 33, supplement 15, Article ID 5500, 2015. View at Google Scholar
  32. W. H. Shen, A. S. Balajee, J. Wang et al., “Essential role for nuclear PTEN in maintaining chromosomal integrity,” Cell, vol. 128, no. 1, pp. 157–170, 2007. View at Publisher · View at Google Scholar · View at Scopus
  33. K. J. Dedes, D. Wetterskog, A. M. Mendes-Pereira et al., “PTEN deficiency in endometrioid endometrial adenocarcinomas predicts sensitivity to PARP inhibitors,” Science Translational Medicine, vol. 2, no. 53, p. 53ra75, 2010. View at Publisher · View at Google Scholar · View at Scopus
  34. M. D. Forster, K. J. Dedes, S. Sandhu et al., “Treatment with olaparib in a patient with PTEN-deficient endometrioid endometrial cancer,” Nature Reviews Clinical Oncology, vol. 8, no. 5, pp. 302–306, 2011. View at Publisher · View at Google Scholar · View at Scopus
  35. R. Siegel, D. Naishadham, and A. Jemal, “Cancer statistics, 2013,” CA Cancer Journal for Clinicians, vol. 63, no. 1, pp. 11–30, 2013. View at Publisher · View at Google Scholar · View at Scopus
  36. D. B. F. Forman, D. H. Brewster, C. Gombe Mbalawa et al., Eds., GLOBOCAN 2012: Estimated Cancer Incidence, Mortality and Prevalence Worldwide in 2012, 2012, http://www.iarc.fr/.
  37. F. X. Bosch, A. Lorincz, N. Muñoz, C. J. L. M. Meijer, and K. V. Shah, “The causal relation between human papillomavirus and cervical cancer,” Journal of Clinical Pathology, vol. 55, no. 4, pp. 244–265, 2002. View at Publisher · View at Google Scholar · View at Scopus
  38. B. I. Bertelsen, S. J. Steine, R. Sandvei, A. Molven, and O. D. Laerum, “Molecular analysis of the PI3K-AKT pathway in uterine cervical neoplasia: frequent PIK3CA amplification and AKT phosphorylation,” International Journal of Cancer, vol. 118, no. 8, pp. 1877–1883, 2006. View at Publisher · View at Google Scholar · View at Scopus
  39. K.-J. Oh, A. Kalinina, N.-H. Park, and S. Bagchi, “Deregulation of eIF4E: 4E-BP1 in differentiated human papillomavirus- containing cells leads to high levels of expression of the E7 oncoprotein,” Journal of Virology, vol. 80, no. 14, pp. 7079–7088, 2006. View at Publisher · View at Google Scholar · View at Scopus
  40. I. Beuvink, A. Boulay, S. Fumagalli et al., “The mTOR inhibitor RAD001 sensitizes tumor cells to DNA-damaged induced apoptosis through inhibition of p21 translation,” Cell, vol. 120, no. 6, pp. 747–759, 2005. View at Publisher · View at Google Scholar · View at Scopus
  41. A. C. de Melo, R. Grazziotin-Reisner, F. Erlich et al., “A phase I study of mTOR inhibitor everolimus in association with cisplatin and radiotherapy for the treatment of locally advanced cervix cancer: PHOENIX I,” Cancer Chemotherapy and Pharmacology, vol. 78, no. 1, pp. 101–109, 2016. View at Publisher · View at Google Scholar · View at Scopus
  42. J. W. Moroney, M. P. Schlumbrecht, T. Helgason et al., “A phase I trial of liposomal doxorubicin, bevacizumab, and temsirolimus in patients with advanced gynecologic and breast malignancies,” Clinical Cancer Research, vol. 17, no. 21, pp. 6840–6846, 2011. View at Publisher · View at Google Scholar · View at Scopus
  43. S. A. Piha-Paul, J. J. Wheler, S. Fu et al., “Advanced gynecologic malignancies treated with a combination of the VEGF inhibitor bevacizumab and the mTOR inhibitor temsirolimus,” Oncotarget, vol. 5, no. 7, pp. 1846–1855, 2014. View at Publisher · View at Google Scholar · View at Scopus
  44. A. V. Tinker, S. Ellard, S. Welch et al., “Phase II study of temsirolimus (CCI-779) in women with recurrent, unresectable, locally advanced or metastatic carcinoma of the cervix. A trial of the NCIC Clinical Trials Group (NCIC CTG IND 199),” Gynecologic Oncology, vol. 130, no. 2, pp. 269–274, 2013. View at Publisher · View at Google Scholar · View at Scopus
  45. Á. H. I. Garces, M. S. F. Dias, E. Paulino, C. G. M. Ferreira, and A. C. De Melo, “Treatment of ovarian cancer beyond chemotherapy: are we hitting the target?” Cancer Chemotherapy and Pharmacology, vol. 75, no. 2, pp. 221–234, 2015. View at Publisher · View at Google Scholar · View at Scopus
  46. I. Romero and R. C. Bast Jr., “Minireview: human ovarian cancer: biology, current management, and paths to personalizing therapy,” Endocrinology, vol. 153, no. 4, pp. 1593–1602, 2012. View at Publisher · View at Google Scholar · View at Scopus
  47. T. Gui and K. Shen, “The epidermal growth factor receptor as a therapeutic target in epithelial ovarian cancer,” Cancer Epidemiology, vol. 36, no. 5, pp. 490–496, 2012. View at Publisher · View at Google Scholar · View at Scopus
  48. https://www.nccn.org/professionals/physician_gls/pdf/ovarian.pdf.
  49. G. Emons, C. Kurzeder, B. Schmalfeldt et al., “Temsirolimus in women with platinum-refractory/resistant ovarian cancer or advanced/recurrent endometrial carcinoma. A phase II study of the AGO-study group (AGO-GYN8),” Gynecologic Oncology, vol. 140, no. 3, pp. 450–456, 2016. View at Publisher · View at Google Scholar · View at Scopus
  50. Available on ECO, European Cancer Observatory. International agency for research on cancer, http://eu-cancer.iarc.fr.
  51. B. Cheaib, A. Auguste, and A. Leary, “The PI3K/Akt/mTOR pathway in ovarian cancer: therapeutic opportunities and challenges,” Chinese Journal of Cancer, vol. 34, no. 1, pp. 4–16, 2015. View at Publisher · View at Google Scholar · View at Scopus
  52. A. D. Bois, A. Reuss, E. Pujade-Lauraine, P. Harter, I. Ray-Coquard, and J. Pfisterer, “Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the arbeitsgemeinschaft gynaekologische onkologie studiengruppe ovarialkarzinom (AGO-OVAR) and the groupe d'Investigateurs nationaux pour les etudes des cancers de l'Ovaire (GINECO),” Cancer, vol. 115, no. 6, pp. 1234–1244, 2009. View at Publisher · View at Google Scholar · View at Scopus
  53. F. Musa, A. Alard, G. David-West, J. P. Curtin, S. V. Blank, and R. J. Schneider, “Dual mTORC1/2 inhibition as a novel strategy for the resensitization and treatment of platinum-resistant ovarian cancer,” Molecular Cancer Therapeutics, vol. 15, no. 7, pp. 1557–1567, 2016. View at Publisher · View at Google Scholar · View at Scopus
  54. S. Pignata, L. Cannella, D. Leopardo, C. Pisano, G. S. Bruni, and G. Facchini, “Chemotherapy in epithelial ovarian cancer,” Cancer Letters, vol. 303, no. 2, pp. 73–83, 2011. View at Publisher · View at Google Scholar · View at Scopus
  55. A. Davis, A. V. Tinker, and M. Friedlander, ““platinum resistant” ovarian cancer: what is it, who to treat and how to measure benefit?” Gynecologic Oncology, vol. 133, no. 3, pp. 624–631, 2014. View at Publisher · View at Google Scholar · View at Scopus
  56. T. A. Lawrie, A. Bryant, A. Cameron, E. Gray, and J. Morrison, “Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer,” The Cochrane Database of Systematic Reviews, vol. 7, Article ID CD006910, 2013. View at Google Scholar · View at Scopus
  57. N. Colombo, E. Kutarska, M. Dimopoulos et al., “Randomized, open-label, phase III study comparing patupilone (EPO906) with pegylated liposomal doxorubicin in platinum-refractory or -resistant patients with recurrent epithelial ovarian, primary fallopian tube, or primary peritoneal cancer,” Journal of Clinical Oncology, vol. 30, no. 31, pp. 3841–3847, 2012. View at Publisher · View at Google Scholar · View at Scopus
  58. J. Sehouli, D. Stengel, P. Harter et al., “Topotecan weekly versus conventional 5-day schedule in patients with platinum-resistant ovarian cancer: a randomized multicenter phase II trial of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study Group,” Journal of Clinical Oncology, vol. 29, no. 2, pp. 242–248, 2011. View at Publisher · View at Google Scholar · View at Scopus
  59. E. Pujade-Lauraine, F. Hilpert, B. Weber et al., “Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial,” Journal of Clinical Oncology, vol. 32, no. 13, pp. 1302–1308, 2014. View at Publisher · View at Google Scholar · View at Scopus
  60. Cancer Genome Atlas Research Network, “Integrated genomic analyses of ovarian carcinoma,” Nature, vol. 474, pp. 609–615, 2011. View at Google Scholar
  61. R. J. Kurman and I.-M. Shih, “Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer—shifting the paradigm,” Human Pathology, vol. 42, no. 7, pp. 918–931, 2011. View at Publisher · View at Google Scholar · View at Scopus
  62. E. Cerami, J. Gao, U. Dogrusoz et al., “The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data,” Cancer Discovery, vol. 2, no. 5, pp. 401–404, 2012. View at Publisher · View at Google Scholar · View at Scopus
  63. K. K. Zorn, T. Bonome, L. Gangi et al., “Gene expression profiles of serous, endometrioid, and clear cell subtypes of ovarian and endometrial cancer,” Clinical Cancer Research, vol. 11, no. 18, pp. 6422–6430, 2005. View at Publisher · View at Google Scholar · View at Scopus
  64. D. A. Levine, F. Bogomolniy, C. J. Yee et al., “Frequent mutation of the PIK3CA gene in ovarian and breast cancers,” Clinical Cancer Research, vol. 11, no. 8, pp. 2875–2878, 2005. View at Publisher · View at Google Scholar · View at Scopus
  65. F. Janku, J. J. Wheler, S. N. Westin et al., “PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations,” Journal of Clinical Oncology, vol. 30, no. 8, pp. 777–782, 2012. View at Publisher · View at Google Scholar · View at Scopus
  66. S. Mabuchi, H. Kuroda, R. Takahashi, and T. Sasano, “The PI3K/AKT/mTOR pathway as a therapeutic target in ovarian cancer,” Gynecologic Oncology, vol. 137, no. 1, pp. 173–179, 2015. View at Publisher · View at Google Scholar · View at Scopus
  67. P. Andorfer, A. Heuwieser, A. Heinzel, A. Lukas, B. Mayer, and P. Perco, “Vascular endothelial growth factor A as predictive marker for mTOR inhibition in relapsing high-grade serous ovarian cancer,” BMC Systems Biology, vol. 10, article no. 33, 2016. View at Publisher · View at Google Scholar
  68. S. Mabuchi, C. Kawase, D. A. Altomare et al., “mTOR is a promising therapeutic target both in cisplatin-sensitive and cisplatin-resistant clear cell carcinoma of the ovary,” Clinical Cancer Research, vol. 15, no. 17, pp. 5404–5413, 2009. View at Publisher · View at Google Scholar · View at Scopus
  69. F. Di Nicolantonio, S. Arena, J. Tabernero et al., “Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus,” The Journal of Clinical Investigation, vol. 120, no. 8, pp. 2858–2866, 2010. View at Publisher · View at Google Scholar · View at Scopus
  70. E. Stover, L. A. Garraway, and U. A. Matulonis, “Somatic alterations in the PTEN-PI3K-AKT-mTOR pathway in a cohort of 379 ovarian cancer patients,” Journal of Clinical Oncology, vol. 34, supplement, abstract 5572, 2016. View at Google Scholar
  71. H. Itamochi and J. Kigawa, “Clinical trials and future potential of targeted therapy for ovarian cancer,” International Journal of Clinical Oncology, vol. 17, no. 5, pp. 430–440, 2012. View at Publisher · View at Google Scholar · View at Scopus
  72. M. Takano, Y. Kikuchi, K. Kudoh et al., “Weekly administration of temsirolimus for heavily pretreated patients with clear cell carcinoma of the ovary: a report of six cases,” International Journal of Clinical Oncology, vol. 16, no. 5, pp. 605–609, 2011. View at Publisher · View at Google Scholar · View at Scopus
  73. M. D. I. Boers-Sonderen, I. Desar, W. T. A. Van Der Graaf, P. B. Ottevanger, and C. Van Herpen, “A phase Ib study of the combination of temsirolimus and pegylated liposomal doxorubcin in advanced or recurrent breast, endometrial and ovarian cancer,” Journal of Clinical Oncology, vol. 30, supplement, abstract 5061, 2012, Proceedings of the 2012 ASCO Annual Meeting. View at Google Scholar
  74. C. Kollmannsberger, H. Hirte, L. L. Siu et al., “Temsirolimus in combination with carboplatin and paclitaxel in patients with advanced solid tumors: a NCIC-CTG, phase I, open-label dose-escalation study (IND 179),” Annals of Oncology, vol. 23, no. 1, Article ID mdr063, pp. 238–244, 2012. View at Publisher · View at Google Scholar · View at Scopus
  75. H. J. P. Chon, P. L. Judson, S. Apte, J. H. Lee, I. Williams-Elson, and R. M. Wenham, “Phase I study of combination carboplatin, paclitaxel and ridaforolimus in patients with solid, endometrial and ovarian cancers,” Journal of Clinical Oncology, vol. 32, abstr 2614, 2014. View at Google Scholar
  76. M. Campone, V. Levy, E. Bourbouloux et al., “Safety and pharmacokinetics of paclitaxel and the oral mTOR inhibitor everolimus in advanced solid tumours,” British Journal of Cancer, vol. 100, no. 2, pp. 315–321, 2009. View at Publisher · View at Google Scholar · View at Scopus
  77. M. K. H. Takano, H. Kouta, Y. Ikeda et al., “Combination chemotherapy with temsirolimus and trabectedin for recurrent clear cell carcinoma of the ovary: a phase II single arm clinical trial,” Journal of Clinical Oncology, vol. 32, abstract 5517, 2014. View at Google Scholar
  78. A. P. Myers, “New strategies in endometrial cancer: targeting the PI3K/mTOR pathway—the devil is in the details,” Clinical Cancer Research, vol. 19, no. 19, pp. 5264–5274, 2013. View at Publisher · View at Google Scholar · View at Scopus